Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2025)
Legend Biotech (LEGN) posted Other Non-Current Liabilities of $8.0 million for Q4 2025, down 1.54% on a QoQ basis from $8.1 million in Q3 2025, and up 31.15% year-over-year from $6.1 million in Q4 2024.
Legend Biotech (LEGN) has 6 years of Other Non-Current Liabilities data on file, last reported at $8.0 million in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 31.15% year-over-year to $8.0 million; the TTM figure through Dec 2025 stood at $8.0 million (up 31.15% YoY), while the FY2025 annual figure was $8.0 million, up 31.15% from the prior year.
- Other Non-Current Liabilities retreated to $8.0 million in Q4 2025, from $8.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.1 million in Q3 2025 and bottomed at $554.0 in Q1 2021.
- A 5-year average of $1.7 million and a median of $224000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 64159.93% — and 2024, when it sank 86.61%.
- Year by year, Other Non-Current Liabilities stood at $396000.0 in 2021, then plunged by 41.16% to $233000.0 in 2022, then slumped by 75.97% to $56000.0 in 2023, then jumped by 10792.86% to $6.1 million in 2024, then soared by 31.15% to $8.0 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $8.0 million (Q4 2025), $8.1 million (Q3 2025), and $6.1 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Sep 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 56,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Jun 30, 2023 | 152,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 233,000.00 |
| Mar 31, 2022 | 356,000.00 |
| Dec 31, 2021 | 396,000.00 |
| Sep 30, 2021 | 991,000.00 |
| Jun 30, 2021 | 554.00 |
| Mar 31, 2021 | 554.00 |
| Dec 31, 2020 | 554,000.00 |